Elsevier

Thrombosis Research

Volume 73, Issue 1, 1 January 1994, Pages 39-52
Thrombosis Research

Paper
Purification and characterization of platelet aggregation inhibitors from snake venoms

https://doi.org/10.1016/0049-3848(94)90052-3Get rights and content

Abstract

Proteins that inhibit glycoprotein (GP) IIb/IIIa mediated platelet aggregation have been purified from the venom of two snake species. A small platelet aggregation inhibitor (pl.AI), multisquamatin (Mr=5,700), was purified from Echis multisquamatus venom by hydrophobic interaction HPLC and two steps on C18 reverse phase HPLC. A larger pl.AI, contortrostatin (Mr=15,000), was purified by a similar HPLC procedure from the venom of Agkistrodon contortrix contortrix. Both pl.AIs inhibit ADP-induced human, canine and rabbit platelet aggregation using platelet rich plasma (PRP). Multisquamatin has an IC50 of 97 nM, 281 nM and 333 nM for human, canine and rabbit PRP, respectively. Contortrostatin has an IC50 of 49 nM, 120 nM and 1,150 nM for human, canine and rabbit PRP, respectively. In a competitive binding assay using 125I-7E3 (a monoclonal antibody to GPIIb/IIIa that inhibits platelet aggregation) both contortrostatin and multisquamatin demonstrated GPIIb/IIIa specific binding to human and canine platelets. The IC50 for contortrostatin displacement of 7E3 binding to human and canine GPIIb/IIIa is 27 nM and 16 nM, respectively and for multisquamatin it is 3 nM and 63 nM, respectively. Our results indicate that both pl.AIs inhibit platelet aggregation by binding with high affinity to GPIIb/IIIa.

References (25)

Cited by (71)

  • Preclinical studies of a novel snake venom-derived recombinant disintegrin with antitumor activity: A review

    2020, Biochemical Pharmacology
    Citation Excerpt :

    Many of them were characterized structurally and functionally and were confirmed to interact with and inhibit specific integrins, generating further efforts to study their potential anticancer activities. In our own studies, the Markland lab discovered contortrostatin (CN) in 1994 [41,42] a homodimeric disintegrin from the venom of Agkistrodon contortrix contortrix, the Southern copperhead snake (Fig. 1). CN has become one of the most-studied members of this group of snake venom disintegrins.

  • Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential

    2012, Toxicon
    Citation Excerpt :

    When proteolysis was complete, the proteolyzed lysates were passed through a 0.22 μm filter, diluted 1:100 in ddH2O, ultrafiltrated through a 50,000 MWCO cartridge (Biomax50, Millipore) and then reconcentrated against a 5000 MWCO cartridge (Biomax5, Millipore) using a tangential flow ultrafiltration device (Labscale TFF system, Millipore). Purification was accomplished by C-18 reverse phase HPLC using the standard elution conditions previously employed for the purification of native CN (Trikha et al., 1994b). The filtrated lysates processed as described above were loaded onto a Vydac C-18 column (218TP54, Temecula, CA).

  • Biochemistry of Envenomation

    2012, Advances in Clinical Chemistry
View all citing articles on Scopus
View full text